Pascal Deschatelets Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Pascal Deschatelets is Chief Scientific Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 1.14 Million shares of APLS, which is worth approximately $37.3 Million. The most recent transaction as insider was on Aug 08, 2022, when has been sold 12,000 shares (Common Stock) at a price of $62.5 per share, resulting in proceeds of $750,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.14M

0% 3M change

2.12% 12M change

Total Value Held $37.3 Million

Pascal Deschatelets Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 08 2022	SELL Open market or private sale	$750,000 $62.5 p/Share	12,000 Reduced 1.25%	944,280 Common Stock
Aug 08 2022	BUY Exercise of conversion of derivative security	$49,395 $2.67 p/Share	18,500 Added 1.9%	956,280 Common Stock
Jul 08 2022	SELL Open market or private sale	$575,400 $47.95 p/Share	12,000 Reduced 1.26%	937,780 Common Stock
Jul 08 2022	BUY Exercise of conversion of derivative security	$49,395 $2.67 p/Share	18,500 Added 1.91%	949,780 Common Stock
Jun 17 2022	BUY Exercise of conversion of derivative security	$88,123 $2.67 p/Share	33,005 Added 3.42%	931,280 Common Stock
Jun 08 2022	SELL Open market or private sale	$529,080 $44.09 p/Share	12,000 Reduced 1.33%	891,775 Common Stock
Jun 08 2022	BUY Exercise of conversion of derivative security	$49,395 $2.67 p/Share	18,500 Added 2.02%	898,275 Common Stock
Apr 29 2022	SELL Open market or private sale	$177,720 $44.43 p/Share	4,000 Reduced 0.45%	891,775 Common Stock
Apr 29 2022	BUY Exercise of conversion of derivative security	$10,680 $2.67 p/Share	4,000 Added 0.44%	895,775 Common Stock
Apr 21 2022	SELL Other acquisition or disposition	-	1,875 Reduced 0.21%	891,775 Common Stock
Feb 10 2022	SELL Payment of exercise price or tax liability	$49,806 $47.12 p/Share	1,057 Reduced 0.12%	893,650 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$35,927 $38.59 p/Share	931 Reduced 0.1%	894,707 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	26,051 Added 2.83%	895,638 Common Stock
Jun 24 2021	SELL Open market or private sale	$410,063 $65.61 p/Share	6,250 Reduced 0.71%	869,587 Common Stock
Jun 24 2021	BUY Exercise of conversion of derivative security	$16,688 $2.67 p/Share	6,250 Added 0.71%	875,837 Common Stock
May 24 2021	SELL Open market or private sale	$296,250 $47.4 p/Share	6,250 Reduced 0.71%	869,587 Common Stock
May 24 2021	BUY Exercise of conversion of derivative security	$16,688 $2.67 p/Share	6,250 Added 0.71%	875,837 Common Stock
Apr 28 2021	BUY Exercise of conversion of derivative security	$12,015 $2.67 p/Share	4,500 Added 0.51%	869,587 Common Stock
Apr 23 2021	SELL Open market or private sale	$288,313 $46.13 p/Share	6,250 Reduced 0.72%	865,087 Common Stock
Apr 23 2021	BUY Exercise of conversion of derivative security	$16,688 $2.67 p/Share	6,250 Added 0.71%	871,337 Common Stock
Mar 10 2021	SELL Open market or private sale	$317,125 $50.74 p/Share	6,250 Reduced 0.72%	865,087 Common Stock
Mar 10 2021	BUY Exercise of conversion of derivative security	$16,688 $2.67 p/Share	6,250 Added 0.71%	871,337 Common Stock
Feb 10 2021	SELL Payment of exercise price or tax liability	$32,831 $47.72 p/Share	688 Reduced 0.08%	865,087 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	9,375 Added 1.07%	865,775 Common Stock

Pascal Deschatelets

Chief Scientific Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account